ROSALIND ADVISORS INC
Q2 2026 Form 13-F
TORONTO, ONTARIO, CANADA
CIK 0001622627
· Institutional investment manager
$269.2M Reported Value Total
Reported value
$269.2M
Quarter over quarter
+16.5%
Holdings
29
Top-10 concentration
74.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Steven Salamon
President, Rosalind Advisors, Inc.
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $269.2M |
| Positions | 29 |
| Change in reported value | +8.2% |
| New positions | 3 |
| Exited positions | 6 |
| Position turnover | 25.7% |
| Top-10 concentration | 74.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
35 | $311.9M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
29 | $269.2M |
|
Q1 2026 13F
Filed May 14, 2026
|
32 | $248.9M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
29 | $284.5M |
|
Q3 2025 13F
Filed Nov 13, 2025
|
29 | $292.6M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $210.9M |
|
Q1 2025 13F
Filed May 14, 2025
|
31 | $205.6M |
|
Q4 2024 13F
Filed Feb 11, 2025
|
28 | $195.6M |
|
Q3 2024 13F
Filed Oct 30, 2024
|
29 | $156.2M |
|
Q2 2024 13F
Filed Jul 12, 2024
|
35 | $130.0M |
|
Q1 2024 13F
Filed Apr 25, 2024
|
31 | $107.0M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
27 | $121.4M |
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | DCTH DELCATH SYSTEMS, INC. | $41.6M | 15.44% |
| 2 | FENC FENNEC PHARMACEUTICALS INC | $34.3M | 12.73% |
| 3 | XERS XERIS BIOPHARMA HOLDINGS INC | $23.0M | 8.56% |
| 4 | SVRA SAVARA INC | $19.6M | 7.27% |
| 5 | VSTM VERASTEM INC | $15.2M | 5.66% |
| 6 | XFOR X4 PHARMACEUTICALS INC | $15.0M | 5.58% |
| 7 | EYPT EYEPOINT PHARMACEUTICALS INC | $14.1M | 5.25% |
| 8 | CYBN CYBIN INC | $12.9M | 4.8% |
| 9 | VOR VOR BIOPHARMA INC | $11.9M | 4.44% |
| 10 | PCVX VAXCYTE INC | $11.6M | 4.32% |
| 11 | MDWD MEDIWOUND LTD | $11.0M | 4.09% |
| 12 | CLDX CELLDEX THERAPEUTICS INC | $7.4M | 2.76% |
| 13 | BCRX BIOCRYST PHARMACEUTICALS INC | $7.2M | 2.68% |
| 14 | PROF PROFOUND MEDICAL CORP | $5.5M | 2.05% |
| 15 | TLPH TALPHERA INC | $5.3M | 1.98% |
| 16 | AVIR ATEA PHARMACEUTICALS INC | $5.0M | 1.85% |
| 17 | MYO MYOMO INC | $3.8M | 1.41% |
| 18 | OVID OVID THERAPEUTICS INC | $3.0M | 1.11% |
| 19 | NRXS NEURAXIS INC | $3.0M | 1.1% |
| 20 | ABVX ABIVAX SA | $2.8M | 1.03% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.